-40.00% percent quarterly performance for Bionano Genomics Inc (BNGO) is not indicative of the underlying story

Bionano Genomics Inc (NASDAQ: BNGO) kicked off on Friday, down -4.73% from the previous trading day, before settling in for the closing price of $0.79. Over the past 52 weeks, BNGO has traded in a range of $0.71-$8.20.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 32.87%. While this was happening, its average annual earnings per share was recorded 72.17%. With a float of $60.58 million, this company’s outstanding shares have now reached $61.23 million.

Considering the fact that the conglomerate employs 344 people, you should pay attention to its efficiency factor.

Bionano Genomics Inc (BNGO) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Bionano Genomics Inc is 1.07%, while institutional ownership is 10.13%. The most recent insider transaction that took place on Jun 13 ’23, was worth 50,000. In this transaction Director of this company bought 65,789 shares at a rate of $0.76, taking the stock ownership to the 65,789 shares. Before that another transaction happened on May 16 ’23, when Company’s President and CEO bought 15,000 for $0.64, making the entire transaction worth $9,639. This insider now owns 806,474 shares in total.

Bionano Genomics Inc (BNGO) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.75 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 72.17% per share during the next fiscal year.

Bionano Genomics Inc (NASDAQ: BNGO) Trading Performance Indicators

Take a look at Bionano Genomics Inc’s (BNGO) current performance indicators. Last quarter, stock had a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.27.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.64, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -1.27 in one year’s time.

Technical Analysis of Bionano Genomics Inc (BNGO)

Compared to the last year’s volume of 1.68 million, its volume of 1.93 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 12.18%. Additionally, its Average True Range was 0.09.

During the past 100 days, Bionano Genomics Inc’s (BNGO) raw stochastic average was set at 2.29%, which indicates a significant decrease from 8.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.08% in the past 14 days, which was lower than the 76.38% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.0912, while its 200-day Moving Average is $2.3115. Nevertheless, the first resistance level for the watch stands at $0.7900 in the near term. At $0.8300, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8500. If the price goes on to break the first support level at $0.7300, it is likely to go to the next support level at $0.7100. Should the price break the second support level, the third support level stands at $0.6700.

Bionano Genomics Inc (NASDAQ: BNGO) Key Stats

The company with the Market Capitalisation of 45.92 million has total of 54,694K Shares Outstanding. Its annual sales at the moment are 36,120 K in contrast with the sum of -232,490 K annual income. Company’s last quarter sales were recorded 10,720 K and last quarter income was -43,890 K.